Insider Trading activities of Fate Therapeutics Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Fate Therapeutics Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Fate Therapeutics Inc since year 2005. Table 2 shows the detailed insider transactions of Fate Therapeutics Inc since 2005. The reporting company's ticker symbol is FATE. The reporting company's CIK number is 1434316.
The total value of stock buying since 2005 is $76,849,985.
The total value of stock sales since 2005 is $17,780,795.
The total value of stock option exercises since 2005 is $472,318.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Fate Therapeutics Inc (FATE).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2019-03 0 $0 45,000 $755,860 45,000 $105,099
2019-02 0 $0 25,000 $401,825 25,000 $72,500
2019-01 0 $0 375,000 $5,412,122 25,000 $47,825
2018-12 0 $0 650,000 $10,457,057 0 $0
2018-09 3,703,704 $50,000,004 0 $0 0 $0
2018-05 0 $0 0 $0 21,054 $124,113
2017-10 0 $0 38,484 $148,925 0 $0
2016-11 469,922 $1,249,991 0 $0 0 $0
2016-08 0 $0 0 $0 2,570 $3,520
2016-01 0 $0 0 $0 7,500 $11,250
2015-04 0 $0 0 $0 33,000 $46,250
2014-06 0 $0 9,793 $68,551 8,447 $13,290
2014-05 0 $0 9,793 $69,197 8,447 $13,033
2014-04 0 $0 21,254 $187,952 24,751 $35,438
2014-03 0 $0 27,326 $279,306 0 $0
2013-10 4,266,665 $25,599,990 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Fate Therapeutics Inc insiders (FATE)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2019-03-21 Wolchko J Scott (President and CEO) Sale 20,000 17.61 352,160
2019-03-21 Wolchko J Scott (President and CEO) Option Ex 20,000 1.63 32,599
2019-03-01 Tahl Cindy (General Counsel and Secretary) Sale 25,000 16.15 403,700
2019-03-01 Tahl Cindy (General Counsel and Secretary) Option Ex 25,000 2.90 72,500
2019-02-25 Tahl Cindy (General Counsel and Secretary) Sale 25,000 16.07 401,825
2019-02-25 Tahl Cindy (General Counsel and Secretary) Option Ex 25,000 2.90 72,500
2019-01-30 Nashat Amir (Director) Sale 53,017 14.16 750,985
2019-01-29 Nashat Amir (Director) Sale 97,500 14.16 1,380,795
2019-01-28 Nashat Amir (Director) Sale 70,000 13.78 964,740
2019-01-25 Nashat Amir (Director) Sale 90,000 14.14 1,272,780
2019-01-18 Nashat Amir (Director) Sale 39,483 16.28 642,822
2019-01-07 Tahl Cindy (General Counsel and Secretary) Sale 25,000 16.00 400,000
2019-01-07 Tahl Cindy (General Counsel and Secretary) Option Ex 25,000 1.91 47,825
2018-12-20 Nashat Amir (Director) Sale 33,474 12.25 410,156
2018-12-19 Nashat Amir (Director) Sale 91,210 13.58 1,238,358
2018-12-13 Nashat Amir (Director) Sale 17,788 16.67 296,561
2018-12-12 Nashat Amir (Director) Sale 425,000 16.78 7,132,775
2018-12-11 Nashat Amir (Director) Sale 82,528 16.71 1,379,207
2018-09-25 Green Jeremy Buy 3,703,704 13.50 50,000,004
2018-05-15 Abbot Stewart (Chief Development Officer) Option Ex 21,054 5.89 124,113
2017-10-16 Tahl Cindy (General Counsel and Secretary) Sale 500 4.10 2,050
2017-10-16 Wolchko J Scott (President and CEO) Sale 800 4.07 3,256
2017-10-16 Shoemaker Daniel D (Chief Scientific Officer) Sale 700 4.08 2,856
2017-10-13 Tahl Cindy (General Counsel and Secretary) Sale 7,591 3.83 29,073
2017-10-13 Wolchko J Scott (President and CEO) Sale 16,368 3.87 63,344
2017-10-13 Shoemaker Daniel D (Chief Scientific Officer) Sale 12,525 3.86 48,346
2016-11-23 Storgard Chris (Chief Medical Officer) Buy 37,593 2.66 99,997
2016-11-23 Coughlin Timothy P (Director) Buy 56,390 2.66 149,997
2016-11-23 Rastetter William H (Director) Buy 375,939 2.66 999,997
2016-08-23 Wolchko J Scott (President and CEO) Option Ex 2,570 1.37 3,520
2016-01-18 Wolchko J Scott (President and CEO) Option Ex 7,500 1.50 11,250
2015-04-13 Wolchko J Scott (See Remarks) Option Ex 8,000 1.50 12,000
2015-04-13 Weyer Christian (See Remarks) Option Ex 25,000 1.37 34,250
2014-06-12 Flynn Peter D (See remarks) Sale 5,471 7.00 38,297
2014-06-12 Flynn Peter D (See remarks) Option Ex 5,471 1.54 8,441
2014-06-11 Flynn Peter D (See remarks) Sale 1,017 7.00 7,119
2014-06-11 Flynn Peter D (See remarks) Option Ex 1,017 1.63 1,657
2014-06-10 Flynn Peter D (See remarks) Sale 1,350 7.00 9,450
2014-06-10 Flynn Peter D (See remarks) Option Ex 699 1.63 1,139
2014-06-09 Flynn Peter D (See remarks) Sale 1,955 7.00 13,685
2014-06-09 Flynn Peter D (See remarks) Option Ex 1,260 1.63 2,053
2014-05-01 Flynn Peter D (See remarks) Sale 9,793 7.07 69,197
2014-05-01 Flynn Peter D (See remarks) Option Ex 8,447 1.54 13,033
2014-04-04 Flynn Peter D (See remarks) Sale 5,889 8.34 49,108
2014-04-04 Flynn Peter D (See remarks) Option Ex 5,889 1.63 9,599
2014-04-03 Wolchko J Scott (See remarks) Option Ex 8,862 1.37 12,140
2014-04-02 Weyer Christian (See remarks) Sale 2,262 9.02 20,394
2014-04-02 Weyer Christian (See remarks) Option Ex 2,262 1.37 3,098
2014-04-01 Flynn Peter D (See remarks) Sale 1,346 9.05 12,177
2014-04-01 Wolchko J Scott (See remarks) Sale 4,019 9.08 36,484
2014-04-01 Weyer Christian (See remarks) Sale 7,738 9.02 69,789
2014-04-01 Weyer Christian (See remarks) Option Ex 7,738 1.37 10,601
2014-03-31 Flynn Peter D (See remarks) Sale 2,692 10.43 28,072
2014-03-31 Wolchko J Scott (See remarks) Sale 15,981 10.20 162,974
2014-03-31 Shoemaker Daniel D (Chief Technology Officer) Sale 8,653 10.20 88,260
2013-10-04 Nashat Amir (Director) Buy 833,333 6.00 4,999,998
2013-10-04 Vef Management V, Llc (10% Owner) Buy 833,333 6.00 4,999,998
2013-10-04 Polaris Venture Partners Special Founders' Fund V, L.p. (10% Owner) Buy 833,333 6.00 4,999,998
2013-10-04 Mendlein John (Director) Buy 16,667 6.00 100,002
2013-10-04 Bybee Clinton (10% Owner) Buy 833,333 6.00 4,999,998
2013-10-04 Nelsen Robert (Director) Buy 833,333 6.00 4,999,998
2013-10-04 Rastetter William H (Director) Buy 83,333 6.00 499,998

Insider trading activities including stock purchases, stock sales, and option exercises of FATE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Fate Therapeutics Inc (symbol FATE, CIK number 1434316) see the Securities and Exchange Commission (SEC) website.